Investigating potential anti-proliferative activity of different statins against five cancer cell lines
© 2023 The Authors. Published by Elsevier B.V. on behalf of King Saud University..
Statins have been reported to have potential anti-proliferative effects through an unknown mechanism. This study aims to investigate the anti-proliferative activities of five statins, including simvastatin, rosuvastatin, fluvastatin, atorvastatin, and pravastatin, against five different cancer cell lines; cervical epithelial carcinoma DoTc2 4510, malignant melanoma A-375, muscle Ewing's sarcoma A-673, hepatocellular carcinoma HUH-7, as well as breast cancer cells MCF-7. At 100 µM, simvastatin and atorvastatin significantly inhibited 70% of cellular proliferation. At the same concentration, rosuvastatin and fluvastatin showed about 50% of inhibition only in A-375 and A-673 cancer cells in a time- and dose-dependent manner. Of all the statin drugs used, pravastatin had the least inhibitory effect on all the cancer cell lines. Western Blot analysis showed a decrease in mTOR level, and the expression of p53 tumour suppression and BCL-2 proteins was relatively elevated compared to the untreated cells. Simvastatin and atorvastatin may inhibit cellular proliferation via BCL-2/p53, Bax/Bak, and PI3K/Akt/mTOR signalling pathways. This is the first research to evaluate the anti-cancer effects of simvastatin, rosuvastatin, fluvastatin, atorvastatin, and pravastatin against five different cell lines from distinct origins and provided a relevant comparison of their efficacies for their anti-proliferative activity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society - 31(2023), 5 vom: 01. Mai, Seite 727-735 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sarbassova, Gauhar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Revised 16.05.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jsps.2023.03.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356839028 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356839028 | ||
| 003 | DE-627 | ||
| 005 | 20231226071320.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jsps.2023.03.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356839028 | ||
| 035 | |a (NLM)37181137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sarbassova, Gauhar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Investigating potential anti-proliferative activity of different statins against five cancer cell lines |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. Published by Elsevier B.V. on behalf of King Saud University. | ||
| 520 | |a Statins have been reported to have potential anti-proliferative effects through an unknown mechanism. This study aims to investigate the anti-proliferative activities of five statins, including simvastatin, rosuvastatin, fluvastatin, atorvastatin, and pravastatin, against five different cancer cell lines; cervical epithelial carcinoma DoTc2 4510, malignant melanoma A-375, muscle Ewing's sarcoma A-673, hepatocellular carcinoma HUH-7, as well as breast cancer cells MCF-7. At 100 µM, simvastatin and atorvastatin significantly inhibited 70% of cellular proliferation. At the same concentration, rosuvastatin and fluvastatin showed about 50% of inhibition only in A-375 and A-673 cancer cells in a time- and dose-dependent manner. Of all the statin drugs used, pravastatin had the least inhibitory effect on all the cancer cell lines. Western Blot analysis showed a decrease in mTOR level, and the expression of p53 tumour suppression and BCL-2 proteins was relatively elevated compared to the untreated cells. Simvastatin and atorvastatin may inhibit cellular proliferation via BCL-2/p53, Bax/Bak, and PI3K/Akt/mTOR signalling pathways. This is the first research to evaluate the anti-cancer effects of simvastatin, rosuvastatin, fluvastatin, atorvastatin, and pravastatin against five different cell lines from distinct origins and provided a relevant comparison of their efficacies for their anti-proliferative activity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Cell signalling | |
| 650 | 4 | |a P53 | |
| 650 | 4 | |a Proliferation | |
| 650 | 4 | |a Statins | |
| 650 | 4 | |a mTOR | |
| 700 | 1 | |a Nurlan, Nurbek |e verfasserin |4 aut | |
| 700 | 1 | |a Raddam Al Shammari, Basim |e verfasserin |4 aut | |
| 700 | 1 | |a Francis, Nidhish |e verfasserin |4 aut | |
| 700 | 1 | |a Alshammari, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Aljofan, Mohamad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society |d 1998 |g 31(2023), 5 vom: 01. Mai, Seite 727-735 |w (DE-627)NLM096450681 |x 1319-0164 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:5 |g day:01 |g month:05 |g pages:727-735 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jsps.2023.03.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 5 |b 01 |c 05 |h 727-735 | ||